

Calmasol-440, solution for infusion for cattle, sheep and pigs

Authorised

- Boric acid
- Magnesium chloride hexahydrate
- Calcium gluconate monohydrate

Product identification

Medicine name:

Calmasol-440, solution for infusion for cattle, sheep and pigs

Calmafusion 380 mg/60 mg/50 mg innrennsliðlyf, lausn fyrir nautgripi, sauðfé og svín

Active substance:

Boric acid

Magnesium chloride hexahydrate

Calcium gluconate monohydrate

Target species:

Cattle

Sheep

Pig

Route of administration:

Intravenous use

Product details

Active substance and strength:

Boric acid

50.00 milligram(s) / 1.00 millilitre(s)

Magnesium chloride hexahydrate

60.00 milligram(s) / 1.00 millilitre(s)

Calcium gluconate monohydrate

380.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for infusion

Withdrawal period by route of administration:

Intravenous use:

-

Cattle

- Meat and offal. 0 day

- Milk. 0 hour

-

Sheep

- Meat and offal. 0 day

- Milk. 0 hour

-

Pig

- Meat and offal. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QA12AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Iceland

Package description:

Graduated polypropylene bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. 12x500 ml.

Graduated polypropylene bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. 1x500 ml.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Interchemie Werken De Adelaar Eesti AS

Marketing authorisation date:

27/11/2019

Manufacturing sites for batch release:

Interchemie Werken De Adelaar Eesti AS

Responsible authority:

Icelandic Medicines Agency

Authorisation number:

IS/2/19/016/01

Date of authorisation status change:

27/11/2019

Reference member state:

Estonia

Procedure number:

EE/V/0104/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Finland France
Germany Greece Hungary Iceland Ireland Italy Latvia Malta Netherlands
Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF)

Published on: 25/07/2025

[Download](#)

Labelling

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.